Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
prostatic acid phosphatase-sargramostim fusion protein
- Development stage
- Approved
- Lead developer
- Dendreon
- Modality
- Dendritic Cell Vaccines → Immune Effector Cells → Other Cell Types → Cell Therapies, Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes, Vaccines & Immunotherapeutics
- Administration
- Intravenous
01
Overview
Prostatic acid phosphatase-sargramostim fusion protein (PA2024) is the active recombinant fusion protein component of **sipuleucel-T** (Provenge), an autologous cellular immunotherapy for prostate cancer. It consists of human prostatic acid phosphatase (PAP), a prostate-specific tumor antigen, linked to human granulocyte-macrophage colony-stimulating factor (GM-CSF/sargramostim), which serves as an immune-cell activator and adjuvant. In the production of sipuleucel-T, a patient's peripheral blood mononuclear cells (PBMCs), including antigen-presenting cells (APCs), are harvested via leukapheresis and incubated ex vivo with PA2024. The GM-CSF portion directs the fusion protein to APCs and promotes their maturation, while the PAP portion is processed and presented on the APC surface. When reinfused into the patient, these activated APCs stimulate a T-cell mediated immune response against PAP-expressing prostate cancer cells.
- Brand names
- Provenge
- Other names
- PAP-GM-CSF fusion proteinprostatic acid phosphatase-sargramostim fusion protein
02
Targets
PAP (Prostatic acid phosphatase)CSF2R (Granulocyte-macrophage colony-stimulating factor receptor)
Beyond the preview
Go deeper on prostatic acid phosphatase-sargramostim fusion protein.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on prostatic acid phosphatase-sargramostim fusion protein.